13F filer · CIK 1652044 ↗
Alphabet Inc.
You are looking at Q2 2020. See the latest, Q2 2026 →
Reported value
$2.17B
+42% on the quarter before
Positions
24
0 new · 1 sold out
Top 10
95.3%
of the value
Est. gain
+$708.0M
on stocks held all quarter
Est. return
+48.5%
on those stocks since Q1 2020
Positions as of Jun 30, 2020, from Alphabet Inc.'s 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.
Portfolio at a glance
- New
- Added
- Cut
- Same
- Options
Each tile is a position, sized by its share, colored by what the fund did with it since Q1 2020. Striped tiles are options.
Largest buys
Since Q1 2020, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
No buys this quarter.
Largest sells
Since Q1 2020, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Vir Biotechnology Inc~$57.1MSold out · 3.7% → 0.0%−1,666,666 shares
- CrowdStrike~$14.0MCut · 0.6% → 0.1%−140,000 shares
- Fulcrum Therapeutics Inc~$803,816Cut · 0.6% → 0.6%−43,949 shares
- Autolus Therapeutics Plc~$17,472Cut · 0.3% → 0.5%−1,090 shares
- Lyft Inc~$15,020Cut · 22.6% → 19.5%−455 shares
Holdings
As of Jun 30, 2020. Changes are in shares against Mar 31, 2020, so a price move alone never reads as a buy or a sale.
| Holding | Value | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jd Com IncSPON ADR CL A · shares 0% · price +48.6% | 37.6% | $815.6M | +$266.7M | ||||||||
| Lyft IncCL A COM · shares −0.00% · price +22.9% | 19.5% | $423.5M | +$79.0M | ||||||||
| Dexcom IncCOM · shares 0% · price +50.6% | 15.1% | $326.6M | +$109.7M | ||||||||
| 1life Healthcare IncCOM · shares 0% · price +100.1% | 10.4% | $224.6M | +$112.3M | ||||||||
| Arcus Biosciences IncCOM · shares 0% · price +78.2% | 5.8% | $124.9M | +$54.8M | ||||||||
| SchrödingerCOM · shares 0% · price +112.4% | 1.9% | $41.1M | +$21.7M | ||||||||
| Slack Technologies Inc.COM CL A · shares 0% · price +15.8% | 1.9% | $40.4M | +$5.5M | ||||||||
| Magenta Therapeutics IncCOM · shares 0% · price +19.6% | 1.2% | $25.1M | +$4.1M | ||||||||
| Rapt Therapeutics IncCOM · shares 0% · price +36.4% | 1.1% | $24.3M | +$6.5M | ||||||||
| Beam Therapeutics IncCOM · shares 0% · price +55.6% | 0.86% | $18.6M | +$6.6M | ||||||||
| Spero Therapeutics IncCOM · shares 0% · price +67.4% | 0.69% | $15.1M | +$6.1M | ||||||||
| Fulcrum Therapeutics IncCOM · shares −6.1% · price +53.2% | 0.58% | $12.5M | +$4.3M | ||||||||
| SnapCL A · shares 0% · price +97.6% | 0.57% | $12.3M | +$6.1M | ||||||||
| Autolus Therapeutics PlcSPON ADS · shares −0.2% · price +167.6% | 0.52% | $11.2M | +$7.0M | ||||||||
| Ideaya Biosciences IncCOM · shares 0% · price +244.9% | 0.49% | $10.7M | +$7.6M | ||||||||
| Cortexyme IncCOM · shares 0% · price +1.5% | 0.40% | $8.8M | +$130,000 | ||||||||
| Gritstone Oncology IncCOM · shares 0% · price +14.1% | 0.28% | $6.2M | +$762,000 | ||||||||
| Mohawk Group Hldgs IncCOM · shares 0% · price +224.8% | 0.27% | $5.8M | +$4.0M | ||||||||
| Cloudera IncCOM · shares 0% · price +61.6% | 0.25% | $5.4M | +$2.1M | ||||||||
| Evelo Biosciences IncCOM · shares 0% · price +30.5% | 0.24% | $5.2M | +$1.2M | ||||||||
| Alector IncCOM · shares 0% · price +1.3% | 0.20% | $4.3M | +$54,000 | ||||||||
| CrowdStrikeCL A · shares −82% · price +80.1% | 0.14% | $3.1M | +$1.4M | ||||||||
| UberCOM · shares 0% · price +11.3% | 0.06% | $1.3M | +$131,000 | ||||||||
| Dropbox IncCL A · shares 0% · price +20.3% | 0.01% | $284,000 | +$48,000 | ||||||||
| Total · 24 positions | 100% | $2.17B | +$708.0M |
Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.
What made money
From Q1 2020 to Q2 2020: 24 stocks held throughout, up $708.0M (+48.5%).
- Jd Com Inc+$266.7M+49%
- 1life Healthcare Inc+$112.3M+100%
- Dexcom Inc+$109.7M+51%
- Lyft Inc+$79.0M+23%
- Arcus Biosciences Inc+$54.8M+78%
Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.
Reported value by quarter
The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.
Every quarter's filing
| Quarter | Reported value | Filing | |
|---|---|---|---|
| Q2 2026 | Aug 7, 2026 | $99.08B+2,367% | SEC ↗ |
| Q1 2026 | May 8, 2026 | $4.02B+56% | SEC ↗ |
| Q4 2025 | Feb 13, 2026 | $2.58B+7% | SEC ↗ |
| Q3 2025 | Nov 7, 2025 | $2.41B+13% | SEC ↗ |
| Q2 2025 | Aug 1, 2025 | $2.14B+35% | SEC ↗ |
| Q1 2025 | May 2, 2025 | $1.58B−8% | SEC ↗ |
| Q4 2024 | Feb 7, 2025 | $1.72B−7% | SEC ↗ |
| Q3 2024 | Nov 8, 2024 | $1.84B−7% | SEC ↗ |
| Q2 2024 | Aug 2, 2024 | $1.97B−21% | SEC ↗ |
| Q1 2024 | May 3, 2024 | $2.51B+17% | SEC ↗ |
| Q4 2023 | Feb 9, 2024 | $2.16B+39% | SEC ↗ |
| Q3 2023 | Nov 13, 2023 | $1.56B−16% | SEC ↗ |
| Q2 2023 | Aug 4, 2023 | $1.86B+3% | SEC ↗ |
| Q1 2023 | May 11, 2023 | $1.80B+5% | SEC ↗ |
| Q4 2022 | Feb 14, 2023 | $1.72B−12% | SEC ↗ |
| Q3 2022 | Nov 15, 2022 | $1.96B+6% | SEC ↗ |
| Q2 2022 | Nov 15, 2022 | $1.84B−40% | SEC ↗ |
| Q1 2022 | Nov 15, 2022 | $3.08B−26% | SEC ↗ |
| Q4 2021 | Nov 15, 2022 | $4.14B−2% | SEC ↗ |
| Q3 2021 | Nov 15, 2022 | $4.22B−14% | SEC ↗ |
| Q2 2021 | Nov 15, 2022 | $4.91B+98% | SEC ↗ |
| Q1 2021 | Nov 15, 2022 | $2.48B+19% | SEC ↗ |
| Q4 2020 | Nov 15, 2022 | $2.08B−2% | SEC ↗ |
| Q3 2020 | Nov 15, 2022 | $2.13B−2% | SEC ↗ |
| Q2 2020 | Nov 15, 2022 | $2.17B+42% | SEC ↗ |
| Q1 2020 | Nov 15, 2022 | $1.52B−8% | SEC ↗ |
| Q4 2019 | Nov 15, 2022 | $1.65B−50% | SEC ↗ |
| Q3 2019 | Nov 15, 2022 | $3.33B−37% | SEC ↗ |
| Q2 2019 | Nov 15, 2022 | $5.27B+172% | SEC ↗ |
| Q1 2019 | Nov 15, 2022 | $1.94B+129% | SEC ↗ |
| Q4 2018 | Nov 15, 2022 | $845.8M−19% | SEC ↗ |
| Q3 2018 | Nov 15, 2022 | $1.04B−12% | SEC ↗ |
| Q2 2018 | Nov 15, 2022 | $1.19B+94% | SEC ↗ |
| Q1 2018 | Nov 15, 2022 | $614.8M+67% | SEC ↗ |
| Q4 2017 | Nov 15, 2022 | $368.6M+7% | SEC ↗ |
| Q3 2017 | Nov 15, 2022 | $344.0M−1% | SEC ↗ |
| Q2 2017 | Nov 15, 2022 | $347.4M+10% | SEC ↗ |
| Q1 2017 | Nov 15, 2022 | $316.8M+8% | SEC ↗ |
| Q4 2016 | Nov 15, 2022 | $292.8M+6% | SEC ↗ |
| Q3 2016 | Nov 15, 2022 | $275.2M+31% | SEC ↗ |
| Q2 2016 | Nov 15, 2022 | $209.8M−14% | SEC ↗ |
| Q1 2016 | Nov 15, 2022 | $242.9M | SEC ↗ |